soul trial oral semaglutide cardiovascular outcomes 2024 results mace Canadian Perspectives 2025 Whiteboard on the Novo Nordisk's Semaglutide lowers MACE

Sources Serono Laboratories

"GLP-1s have been shown to reduce progression from prediabetes to type 2 diabetes by 94%, and significantly reduce the risk of major cardiovascular events." He added, "Obesity is connected to 200 comorbidities, including heart disease, kidney disease and 40% of all cancers, which is why addressing the disease early is key." DOCTORS WARN OF 'TRIFECTA' OF CHRONIC ILLNESSES PLAGUING AMERICANS AFTER MAHA REPORT Patients dont have to be diabetic to benefit from GLP-1 medications for weight loss, according to Dr

Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A

What about vitamin C and electrolytes